

\$%^STN;HighlightOn= ***;HighlightOff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 9 NOV 26 MARPAT enhanced with FSORT command
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts
availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 13 DEC 01 ChemPort single article sales feature unavailable
NEWS 14 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 16 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 17 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:24:31 ON 13 JAN 2009

=> ENTER REGISTRY
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION 0.22 0.22
 FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:24:53 ON 13 JAN 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4
 DICTIONARY FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> S tcgtcgccccccggcgccccccSQEN
 20 TCGTCGTTTTCGGTCGTTT/SQEN
 484263 SQL=21
 L1 20 TCGTCGTTTTCGGTCGTTT/SQEN
 (TCGTGTTTTCGGTCGTTT/SQEN AND SQL=21)

=> D SEC NTE LC 20
 'SEC' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
 SAM - Index Name, MF, and structure - no RN
 FIDE - All substance data, except sequence data
 IDE - FIDE, but only 50 names
 SQIDE - IDE, plus sequence data
 SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
 SQD - Protein sequence data, includes RN
 SQD3 - Same as SQD, but 3-letter amino acid codes are used
 SQN - Protein sequence name information, includes RN

EPROP - Table of experimental properties
 PPROP - Table of predicted properties
 PROP - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
 APPS -- Application and Priority Information
 BIB -- CA Accession Number, plus Bibliographic Data
 CAN -- CA Accession Number
 CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
 IND -- Index Data
 IPC -- International Patent Classification
 PATS -- PL, SO
 STD -- BIB, IPC, and NCL

LABS -- ABS, indented, with text labels
 IBIB -- BIB, indented, with text labels
 ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
 HELP FORMATS -- To see detailed descriptions of the predefined formats.
 ENTER DISPLAY FORMAT (IDE):
 ENTER DISPLAY FORMAT (IDE):D SEQ NTE LC 20
 'D' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

EPROP - Table of experimental properties
PPROP - Table of predicted properties
PROP - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):SEQ

10613524Crft.tm

L1 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2009 ACS on STN

SEQ 1 tegtcgttt tcggtcgttt t
===== ===== =
HITS AT: 1-21

RELATED SEQUENCES AVAILABLE WITH SEQLINK

=> SEQLINK
ENTER TYPE OF LINK (EXACT) OR ?:EXACT
ENTER (L1), L# OR ?:L1

L2 20 SEQLINK EXACT L1

=> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 17.25 17.47

FILE 'CAPLUS' ENTERED AT 08:30:45 ON 13 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996) unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jan 2009 VOL 150 ISS 3
FILE LAST UPDATED: 12 Jan 2009 (20090112/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> S L2
L3 10 L2

=> D BIB AB HITSEQ

L3 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1426958 CAPLUS <<LOGINID::20090113>>

DN 150:24195

TI Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity

IN Jurk, Marion; Uhlmann, Eugen

PA Coley Pharmaceutical GmbH, Germany

SO PCT Int. Appl., 71pp.

CODEN: PIXXD2

DT Patent

LA English

FAN,CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2008142513	A2	20081127	WO 2008-IB1206	20080515
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-930764P P 20070518

AB The invention relates to oligonucleotides including at least one backbone modification and a pyrimidine-purine dinucleotide. The invention also relates to pharmaceutical compus. and methods of use thereof.

IT	***1086794-85-5***	***1087356-25-9***	***1087356-26-0***
	1087356-27-1	***1087356-28-2***	***1087356-29-3***
	1087356-30-6	***1087356-31-7***	

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity)

RN 1086794-85-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggtt tcggtcgttt t

RN 1087356-25-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggtt tcggtcgttt t

RN 1087356-26-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggtt tcggtcgtt t

RN 1087356-27-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggtt tcggtcgtt t

RN 1087356-28-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggtt tcggtcgtt t

RN 1087356-29-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggtt tcggtcgtt t

RN 1087356-30-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggtt tcggtcgtt t

RN 1087356-31-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggtt tcggtcgtt t

=> SEQLINK

10613524Crtf.htm

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

FILE 'REGISTRY' ENTERED AT 08:33:05 ON 13 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2009 **HIGHEST RN** 1093181-04-4
DICTIONARY FILE UPDATES: 11 JAN 2009 **HIGHEST RN** 1093181-04-4

New CAS Information Use Policies; enter HELP|USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=> S tcgtcgtttcggtcgttt
L4 0 TCGTCGTTTTCGGTCGT

=> s tcgtcgtttcggtcgttt
L5 0 TCGTCGTTTTCGGTCGTTT

=> S TCGTCGTTTTCGGTCGTTT
L6 0 TCGTCGTTTTCGGTCGTTT

=> S TCGTCGTTTTCGGTCGTTC/SQSN
L7 35 TCGTCGTTTTCGGTCGTTC/SQSN

→ DKWIC SOL 1

J.7. ANSWER 1 OF 35. REGISTRY. COPYRIGHT © 2000 ACS on STN.

SEQ 1 tcgtcggtt tcggtcgtt t
 ===== ===== =
 HITS AT: 1-21

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 SQL 21

=> FILE USPATFULL CAPLUS BIOSIS GENBANK
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 57.52 85.57
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
 ENTRY SESSION
 CA SUBSCRIBER PRICE 0.00 -0.82

FILE 'USPATFULL' ENTERED AT 08:38:10 ON 13 JAN 2009
 CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 08:38:10 ON 13 JAN 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:38:10 ON 13 JAN 2009
 Copyright (c) 2009 The Thomson Corporation

FILE 'GENBANK' ENTERED AT 08:38:10 ON 13 JAN 2009

=> S L7
 L8 24 L7

=> SET DUPORDER FILE
 SET COMMAND COMPLETED

=> DUPREM L8
 DUPREM IS NOT A RECOGNIZED COMMAND
 The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (>).

=> DUP REM L8
 DUPLICATE IS NOT AVAILABLE IN 'GENBANK'.
 ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
 PROCESSING COMPLETED FOR L8
 L9 24 DUP REM L8 (0 DUPLICATES REMOVED)
 ANSWERS '1-10' FROM FILE USPATFULL
 ANSWERS '11-21' FROM FILE CAPLUS
 ANSWERS '22-24' FROM FILE GENBANK

=> D BIB AB HITSEQ
 HITSEQ' IS NOT A VALID FORMAT
 In a multifile environment, a format can only be used if it is valid

in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):D TI PA AB HITRN

D' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):TI

L9 ANSWER 1 OF 24 USPATFULL on STN

TI Immunostimulatory nucleic acids

=> D L9 BIB AB 1-10

L9 ANSWER 1 OF 24 USPATFULL on STN

AN 2007:256269 USPATFULL <>LOGINID::20090113>>

TI Immunostimulatory nucleic acids

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES

Lipford, Grayson B., Watertown, MA, UNITED STATES

Samolowitz, Ulrike, Langenfeld, GERMANY, FEDERAL REPUBLIC OF

Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF

Uhlmann, Eugen, Glashuetten, GERMANY, FEDERAL REPUBLIC OF

Jurk, Marion, Dormagen, GERMANY, FEDERAL REPUBLIC OF

Rankin, Robert, Hemmen, NETHERLANDS

PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (U.S. corporation)

Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation)

PI US 20070224210 A1 20070927

AI US 2006-542845 A1 20061004 (11)

RLI Continuation of Ser. No. US 2003-644052, filed on 19 Aug 2003, PENDING

PRAI US 2002-404479P 20020819 (60)

US 2002-404820P 20020819 (60)

US 2002-429701P 20021127 (60)

US 2003-447377P 20030214 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US

CLMN Number of Claims: 27

ECL Exemplary Claim: 1-94

DRWN 46 Drawing Page(s)

LN.CNT 6547

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a class of soft or semi-soft CpG

immunostimulatory oligonucleotides that are useful for stimulating an immune response.

L9 ANSWER 2 OF 24 USPATFULL on STN

AN 2007:162759 USPATFULL <>LOGINID::20090113>>

TI Immunostimulatory oligoribonucleotides

IN Forsbach, Alexandra, Ratingen, GERMANY, FEDERAL REPUBLIC OF
 Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
 Lipford, Grayson B., Watertown, MA, UNITED STATES
 PA Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF
 (non-U.S. corporation)
 Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (non-U.S.
 corporation)

PI US 20070142315 A1 20070621
 AI US 2006-603978 A1 20061122 (11)
 PRAI US 2005-739529P 20051125 (60)
 US 2006-778989P 20060303 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE, BOSTON, MA,
 02210-2206, US

CLMN Number of Claims: 57

ECL Exemplary Claim: 1

DRWN 13 Drawing Page(s)

LNCNT 4107

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).

L9 ANSWER 3 OF 24 USPATFULL on STN
 AN 2006:248250 USPATFULL <>LOGINID::20090113>>

TI Immunostimulatory oligonucleotides

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
 Samuelowitz, Ulrike, Langenfeld, GERMANY, FEDERAL REPUBLIC OF
 Vollmer, Jorg, Duesseldorf, GERMANY, FEDERAL REPUBLIC OF

PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (U.S.
 corporation)
 Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF
 (non-U.S. corporation)

PI US 20060211644 A1 20060921
 US 20080009455 A9 20080110

AI US 2006-361313 A1 20060224 (11)

PRAI US 2005-655931P 20050224 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
 BOSTON, MA, 02210-2206, US

CLMN Number of Claims: 45

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 2871

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides.

L9 ANSWER 4 OF 24 USPATFULL on STN

AN 2005:69478 USPATFULL <<LOGINID::20090113>>

TI Immunostimulatory nucleic acids

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES

Samuelowit, Ulrike, Langenfeld, GERMANY, FEDERAL REPUBLIC OF
 Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
 Uhlmann, Eugen, Glashuetten, GERMANY, FEDERAL REPUBLIC OF
 Jurk, Marion, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
 Lipford, Grayson, Watertown, MA, UNITED STATES

Rankin, Robert, Hemmen, NETHERLANDS

PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES, 02481
 (U.S. corporation)

Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF,
 D-40764 (U.S. corporation)

PI US 20050059619 A1 20050317

AI US 2003-644052 A1 20030819 (10)

PRAI US 2002-404479P 20020819 (60)

US 2002-404820P 20020819 (60)

US 2002-429701P 20021127 (60)

US 2003-447377P 20030214 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
 BOSTON, MA, 02210-2211

CLMN Number of Claims: 47

ECL Exemplary Claim: 1

DRWN 50 Drawing Page(s)

LN.CNT 6800

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.

L9 ANSWER 5 OF 24 USPATFULL on STN

AN 2004:299901 USPATFULL <<LOGINID::20090113>>

TI Immunostimulatory nucleic acid oil-in-water formulations and related methods of use

IN Davis, Heather L., Dunrobin, CANADA
 McCluskie, Michael J., Ottawa, CANADA

PA Coley Pharmaceutical Group, Ltd., Ottawa, CANADA, K1Y 4S1 (non-U.S.
 corporation)

PI US 20040235770 A1 20041125

AI US 2004-816220 A1 20040401 (10)

PRAI US 2003-461903P 20030410 (60)

US 2003-459920P 20030402 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,

BOSTON, MA, 02210-2211

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 5381

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention involves methods and compositions of an immunostimulatory nucleic acid in oil-in-water emulsions for topical delivery. The compositions can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer.

L9 ANSWER 6 OF 24 USPATFULL on STN

AN 2004:255150 USPATFULL <<LOGINID::20090113>>

TI Nucleic acid compositions for stimulating immune responses

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES

PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)

PI US 20040198680 A1 20041007

AI US 2003-613524 A1 20030703 (10)

PRAI US 2002-394091P 20020703 (60)

DT Utility

FS APPLICATION

LREP Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 4239

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.

L9 ANSWER 7 OF 24 USPATFULL on STN

AN 2004:197343 USPATFULL <<LOGINID::20090113>>

TI Nucleic acid compositions for stimulating immune responses

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES

PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)

PI US 20040152649 A1 20040805

AI US 2003-613736 A1 20030703 (10)

PRAI US 2002-394164P 20020703 (60)

DT Utility

FS APPLICATION

LREP Maria A. Trevisan, 600 Atlantic Avenue, Boston, MA, 02210

CLMN Number of Claims: 98

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 4371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.

L9 ANSWER 8 OF 24 USPATFULL on STN

AN 2004:121057 USPATFULL <<LOGINID::20090113>>

TI Nucleic acid compositions for stimulating immune responses

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
 PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES, 02481
 (U.S. corporation)
 PI US 20040092472 A1 20040513
 AI US 2003-613228 A1 20030703 (10)
 PRAI US 2002-394193P 20020703 (60)
 DT Utility
 FS APPLICATION
 LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
 BOSTON, MA, 02210-2211
 CLMN Number of Claims: 98
 ECL Exemplary Claim: 1
 DRWN 16 Drawing Page(s)
 LN.CNT 4432
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.

L9 ANSWER 9 OF 24 USPATFULL on STN
 AN 2004:88928 USPATFULL <<LOGINID::20090113>>
 TI Nucleic acid compositions for stimulating immune responses
 IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
 PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)
 PI US 20040067905 A1 20040408
 AI US 2003-613749 A1 20030703 (10)
 PRAI US 2002-394090P 20020703 (60)
 DT Utility
 FS APPLICATION
 LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
 BOSTON, MA, 02210-2211
 CLMN Number of Claims: 98
 ECL Exemplary Claim: 1
 DRWN 12 Drawing Page(s)
 LN.CNT 4438
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.

L9 ANSWER 10 OF 24 USPATFULL on STN
 AN 2004:70652 USPATFULL <<LOGINID::20090113>>
 TI Nucleic acid compositions for stimulating immune responses
 IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
 PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)
 PI US 20040053880 A1 20040318
 AI US 2003-613739 A1 20030703 (10)
 PRAI US 2002-393880P 20020703 (60)
 DT Utility
 FS APPLICATION
 LREP Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue,
 Boston, MA, 02210
 CLMN Number of Claims: 98
 ECL Exemplary Claim: 1
 DRWN 16 Drawing Page(s)
 LN.CNT 4668
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.

=> D L9 BIB AB 11-24

NO VALID FORMATS ENTERED FOR FILE 'GENBANK'
In a multifile environment, each file must have at least one valid
format requested. Refer to file specific help messages or the
STNGUIDE file for information on formats available in individual
files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):T1

L9 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity

L9 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 CpG oligonucleotide analogs containing hydrophobic thymidine analogs with enhanced immunostimulatory activity

L9 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry

L9 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Immunostimulatory oligoribonucleotides containing specific sequence motif(s) and targeting the Toll-like receptor 8 pathway

L9 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Adjuvanted vaccine for tularemia comprising killed Francisella strain

L9 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Immunostimulatory oligonucleotides with stabilized internucleotide linkage for treating cancer, allergy, asthma and infection

L9 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Screening for oligonucleotide ligands of toll-like receptors for use as immunomodulators

L9 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Immunostimulatory nucleic acid oil-in-water topical emulsions for use with vaccines

L9 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Sequences of immunostimulatory oligonucleotides and therapeutic use for immune related diseases

L9 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Immunostimulatory nucleic acids for enhancing immune responses to antigen vaccines against cancer, infection, allergy and autoimmune disease

L9 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

T1 Diagnosis and therapy of diseases associated with signal transduction by detection of single nucleotide polymorphism and cytosine methylation in chemically modified genomic DNA

L9 ANSWER 22 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

TITLE (TI): Methods and products for identification and assessment
of trl ligands

L9 ANSWER 23 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

TITLE (TI): Immunostimulatory nucleic acid oil-in-water
formulations and related methods of use

L9 ANSWER 24 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

TITLE (TI): Diagnosis of diseases associated with signal
transduction

=> D L9 BIB AB 11-21

L9 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:1426958 CAPLUS <<LOGINID::20090113>>

DN 150:24195

TI Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory
activity

IN Jurk, Marion; Uhlmann, Eugen

PA Coley Pharmaceutical GmbH, Germany

SO PCT Int. Appl., 71pp.

CODEN: PIXXD2

DT Patent

LA English

FAN,CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2008142513	A2	20081127	WO 2008-JB1206	20080515
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, VG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-930764A1 P 20070518

AB The invention relates to oligonucleotides including at least one backbone
modification and a pyrimidine-purine dinucleotide. The invention also
relates to pharmaceutical compns. and methods of use thereof.

L9 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:705793 CAPLUS <<LOGINID::20090113>>

DN 149:77378

TI CpG oligonucleotide analogs containing hydrophobic thymidine analogs with

enhanced immunostimulatory activity

IN Debelak, Harald; Uhlmann, Eugen; Jurk, Marion
 PA Coley Pharmaceutical G.m.b.H., Germany
 SO PCT Int. Appl., 127pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN,CNT I

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2008068638 A2 20080612 WO 2007-IB4389 20070925
 WO 2008068638 A3 20081113
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
 GB, GD, GE, GH, GM, GT, HN, HR, IU, ID, IL, IN, IS, JP, KE, KG,
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2006-847811P P 20060927

OS MARPAT 149:77378

AB The authors disclose oligonucleotides including at least one lipophilic substituted nucleotide analog and a pyrimidine-purine dinucleotide. In one example, the oligonucleotides, comprising hydrophobic thymidine base analogs 5' and 3' of the CpG motif, shown an enhanced ability to elicit Toll-like receptor 9-dependent responses.

L9 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:292654 CAPLUS <>LOGINID::20090113>>

DN 148:509462

TI Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry

AU Luganini, Anna; Caposio, Patrizia; Landolfo, Santo; Gribaldo, Giorgio

CS Department of Public Health and Microbiology, University of Turin, Turin, Italy

SO Antimicrobial Agents and Chemotherapy (2008), 52(3), 1111-1120

CODEN: AMACQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

AB Studies in animal models have provided evidence that Toll-like receptor 9 (TLR9) agonists, such as synthetic oligodeoxynucleotides (ODNs) that contain immunostimulatory deoxycytidyl-deoxyguanosine (CpG) motifs (CpG ODNs), protect against a wide range of viral pathogens. This antiviral activity has been suggested to be indirect and secondary to CpG-induced cytokines and inflammatory responses triggered through TLR9 activation. However, few studies have addressed the potential of CpG ODNs as direct antiviral agents. Here, the authors report on the ability of some CpG ODNs to directly suppress, almost completely, human cytomegalovirus (HCMV) replication in both primary fibroblasts and endothelial cells. Murine CMV

replication was inhibited as well, whereas no inhibition was obsd. for herpes simplex virus type 1, adenovirus, or vesicular stomatitis virus. The antiviral activity of these ODNs was significantly reduced when they were added after virus adsorption, indicating that their action may be primarily targeted to the very early phases of the HCMV cycle. In fact, the B-class prototype CpG ODN 2006 effectively prevented the nuclear localization of pp65 and input viral DNA, which suggests that it inhibits HCMV entry. Moreover, a CpG 2006 control, ODN 2137 without CpG motifs, also showed a potent inhibitory activity on the HCMV entry phase, indicating that the anticytomegaloviral activity is independent of the CpG motif. In contrast, a phosphodiester version of CpG 2006 showed reduced antiviral activity, indicating that the inhibitory activity is dependent on the phosphorothioate backbone of the ODN. These results suggest that this yet-unrecognized activity of CpG ODNs may be of interest in the development of novel anticytomegaloviral mols.

REC.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

I.9	ANSWER 14 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN AN 2007:585028 CAPLUS <<LOGINID::20090113>> DN 147:8414
TI	Immunostimulatory oligoribonucleotides containing specific sequence motif(s) and targeting the Toll-like receptor 8 pathway
IN	Forsbach, Alexandra; Vollmer, Joerg; Lipford, Grayson B.
PA	Coley Pharmaceutical G.m.b.H., Germany; Coley Pharmaceutical Group, Inc.
SO	PCT Int. Appl., 143pp.
CODEN:	PIXXD2
DT	Patent
LA	English
FAN,CNT 1	
PATENT NO.	KIND DATE APPLICATION NO. DATE
-----	-----
PI WO 2007062107	A2 20070531 WO 2006-US45183 20061122
WO 2007062107	A3 20070712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW	
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA	
AU 2006318464	A1 20070531 AU 2006-318464 20061122
CA 2630738	A1 20070531 CA 2006-2630738 20061122
US 20070142315	A1 20070621 US 2006-603978 20061122
EP 1957647	A2 20080820 EP 2006-838257 20061122
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR	
IN 2008DN04423	A 20080815 IN 2008-DN4423 20080523
CN 101331229	A 20081224 CN 2006-80044030 20080526
KR 2008072934	A 20080807 KR 2008-715356 20080624

PRAI US 2005-739529P P 20051125

US 2006-778989P P 20060303

WO 2006-US45183 W 20061122

AB The invention provides immunostimulatory compns. and use of those compds. in the prepn. of medicaments for the treatment of disease as well as in vitro uses. In particular, the compns. of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Certain sequence-specific RNA motifs, preferably contg. AU-rich sequences, are discovered to be immunostimulatory, stimulating an immune response through Toll-like receptor 8 (TLR8). Differences between interferon-alpha., tumor necrosis factor-alpha., interferon-gamma., and interleukin-12 prodn. are obsd. in oligonucleotides contg. AU vs. GU repetitions. The AU-rich immunostimulatory oligoribonucleotides produce a strong pro-inflammatory cytokine response, with the exception of interferon-alpha. and related mols. Interferon-alpha. is diminished or lacking upon stimulation with these oligoribonucleotides. Thus, compns. of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compns. and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency.

L9 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:284126 CAPLUS <>LOGINID::20090113>>

DN 146:336431

TI Adjuvanted vaccine for tularemia comprising killed Francisella strain

IN Eyles, James Edward; Hartley, Margaret Gillian

PA The Secretary of State for Defence, UK

SO PCT Int. Appl., 32pp.

CODEN: PIXXD2

DT Patent

LA English

FAN,CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2007028985 A2 20070315 WO 2006-GB3296 20060907

WO 2007028985 A3 20070503

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

GB 2443591 A 20080507 GB 2008-4079 20060907

EP 1924279 A2 20080528 EP 2006-779315 20060907

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRAI GB 2005-18203 A 20050907

GB 2005-18305 A 20050908

WO 2006-GB3296 W 20060907

AB This invention relates to new immunogenic compns. and vaccines suitable for preventing or treating tularemia. The strain used by the inventors is *F. tularensis* LVS (live vaccine strain), killed by irradn. Three different adjuvants were used in the examples: ISCOM (AbISCO-100), CpG 7909 (CpG oligodeoxynucleotide), and Alhydrogel (Alum). Mice were immunized either s.c. or i.m. with 1.5 x 10⁹ CFU LVS. The inventors performed the anal. of antibody response and challenge studies. The ELISPOT assay showed that immunization with LVS produced a cytokine recall response profile consistent with a biased Th1 response (high interferon-gamma formation and low interleukin-4 formation).

L9 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:888480 CAPLUS <>LOGINID::20090113>>

DN 145:291047

TI Immunostimulatory oligonucleotides with stabilized internucleotide linkage for treating cancer, allergy, asthma and infection

IN Krieg, Arthur M.; Samulowitz, Ulrike; Vollmer, Joerg

PA Coley Pharmaceutical Group, Inc., USA; Coley Pharmaceutical GmbH

SO PCT Int. Appl., 93pp.

CODEN: PIXXD2

DT Patent

LA English

FAN,CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006091915	A2	20060831	WO 2006-US6778	20060224
WO 2006091915	A3	20070315		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006216493	A1	20060831	AU 2006-216493	20060224
AU 2006216493	A2	20080320		
AU 2006216493	A9	20080403		
CA 259892	A1	20060831	CA 2006-259892	20060224
US 20060211644	A1	20060921	US 2006-361313	20060224
US 2008009455	A9	20080110		
EP 1851314	A2	20071107	EP 2006-736157	20060224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EU, ES, FI, FR, GB, GR, HU, IE, IS, IT, LL, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008531018	T	20080814	JP 2007-557215	20060224
CN 101160401	A	20080409	CN 2006-80012811	20071017
PRAI US 2005-655931P	P	20050224		
WO 2006-US6778	W	20060224		

AB The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides.

RELCNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:934524 CAPLUS <>LOGINID::20090113>>

DN 141:394071

TI Screening for oligonucleotide ligands of toll-like receptors for use as immunomodulators

IN Vollmer, Jocrg; Jurk, Marion; Lipford, Grayson B.; Schetter, Christian;

Forsbach, Alexandra; Krieg, Arthur M.

PA Coley Pharmaceutical G.m.b.H., Germany; Coley Pharmaceutical Group, Inc.

SO PCT Int. Appl., 340 pp.

CODEN: PIIXD2

DT Patent

LA English

FAN,CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2004094671 A2 20041104 WO 2004-US12788 20040422

WO 2004094671 A9 20050127

WO 2004094671 A3 20050922

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BE, BI, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

EP 1631687 A2 20060308 EP 2004-760178 20040422

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRAI US 2003-464586P P 20030422

US 2003-464588P P 20030422

WO 2004-US12788 W 20040422

AB Screening methods to identify ligands, esp. oligonucleotides, for Toll-like receptors that may be useful as immunomodulators. These methods may also be used to assay the biol. activity of preps. contg. a known TLR ligand, e.g. in quality control. The methods involve testing responses induced by activation of a Toll-like receptor, such as changes in cell surface markers or patterns of gene expression, or the use of a reporter gene regulated by a promoter controlled by a.

RELCNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:857435 CAPLUS <>LOGINID::20090113>>

DN 141:337779

TI Immunostimulatory nucleic acid oil-in-water topical emulsions for use with vaccines

IN Davis, Heather L.; McCluskie, Michael J.

PA Coley Pharmaceutical Group, Ltd., Can.

SO PCT Int. Appl., 188 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2004087203 A2 20041014 WO 2004-IB1371 20040401

WO 2004087203 A3 20041223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

AU 2004226605 A1 20041014 AU 2004-226605 20040401

CA 2521050 A1 20041014 CA 2004-2521050 20040401

US 20040235770 A1 20041125 US 2004-816220 20040401

EP 1608403 A2 20051228 EP 2004-725130 20040401

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRAI US 2003-459920P P 20030402

US 2003-461903P P 20030410

WO 2004-IB1371 W 20040401

AB Oil-in-water emulsions contg. an immunostimulatory nucleic acid, such as CpG oligonucleotide, are described for topical administration in the prevention and treatment of infection. The emulsion may also contain other therapeutic agents, including antiviral, antibacterial or antitumor agents. The compus. can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer. In tests with mice infected with human herpesvirus 2, immunostimulation against the virus was superior when the nucleic acids were delivered in an oil-in-water emulsion. Water-in-oil emulsions were no more effective than control treatments.

RECNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:162829 CAPLUS <<LOGINID::20090113>>

DN 140:230578

TI Sequences of immunostimulatory oligonucleotides and therapeutic use for immune related diseases

IN Krieg, Arthur M.; Samulowitz, Ulrike; Vollmer, Joerg; Uhlmann, Eugen;
Jurk, Marion; Lipford, Grayson; Rankin, Robert

PA Coley Pharmaceutical Group, Inc., USA; Coley Pharmaceutical GmbH

SO PCT Int. Appl., 276 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN,CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2004016805	A2	20040226	WO 2003-US25935	20030819
WO 2004016805	A9	20040819		
WO 2004016805	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493753	A1	20040226	CA 2003-2493753	20030819
AU 2003259916	A1	20040303	AU 2003-259916	20030819
US 20050059619	A1	20050317	US 2003-644052	20030819
EP 1538904	A2	20050615	EP 2003-788643	20030819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688192	A	20051026	CN 2003-824039	20030819
JP 2006508693	T	20060316	JP 2005-502069	20030819
BR 2003013414	A	20070731	BR 2003-13414	20030819
NZ 538001	A	20080530	NZ 2003-538001	20030819
RU 2338750	C2	20081120	RU 2005-107708	20030819
IN 2005KN00167	A	20060421	IN 2005-KN167	20050210
NO 2005001469	A	20050519	NO 2005-1469	20050318
US 20070224210	A1	20070927	US 2006-542845	20061004
IN 2007KN02317	A	20080801	IN 2007-KN2317	20070622
KR 2008011247	A	200801131	KR 2008-701536	20080118
PRAI US 2002-404479P	P	20020819		
US 2002-404820P	P	20020819		
US 2002-429701P	P	20021127		
US 2003-447377P	P	20030214		
US 2003-644052	A1	20030819		
WO 2003-US25935	W	20030819		
IN 2005-KN167	A3	20050210		
KR 2005-702841	A3	20050218		

OS MARPAT 140:230578

AB The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.

RECNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:41608 CAPLUS <<LOGINID::20090113>>

DN 140:110112

TI Immunostimulatory nucleic acids for enhancing immune responses to antigen vaccines against cancer, infection, allergy and autoimmune disease

IN Krieg, Arthur M.
 PA Coley Pharmaceutical Group, Inc., USA
 SO PCT Int. Appl., 257 pp.
 CODEN: PIXXD2

DT Patent

LA English

FAN,CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2004005476 A2 20040115 WO 2003-US21113 20030703

WO 2004005476 A3 20040521

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2494508 A1 20040115 CA 2003-2494508 20030703

AU 2003247880 A1 20040123 AU 2003-247880 20030703

US 20040053880 A1 20040318 US 2003-613739 20030703

US 20040067905 A1 20040408 US 2003-613749 20030703

US 20040092472 A1 20040513 US 2003-613228 20030703

US 20040152649 A1 20040805 US 2003-613736 20030703

US 20040198680 A1 20041007 US 2003-613524 20030703

EP 1551221 A2 20050713 EP 2003-763239 20030703
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1678188 A 20051005 CN 2003-820863 20030703

JP 2005532067 T 20051027 JP 2004-519911 20030703

IN 2005KN00122 A 20060106 IN 2005-KN122 20050202

PRAI US 2002-393880P P 20020703

US 2002-394090P P 20020703

US 2002-394091P P 20020703

US 2002-394164P P 20020703

US 2002-394193P P 20020703

WO 2003-US21113 W 20030703

AB: The invention provides immunostimulatory nucleic acids comprising CpG motifs, and methods of use thereof in stimulating immunity. The immunostimulatory nucleic acids are T-rich, poly-T-contg. or poly-G-contg. sequences. The immunostimulatory nucleic acids are formulated in nutritional supplement, capsule, pill, sublingual tablet, parenteral, local, sustained-release, mucosal, oral, nasal, rectal, vaginal, ocular or systemic forms for administration. The immunostimulatory nucleic acids are esp. useful as adjuvant for vaccines against cancer, infection, allergy and autoimmune disease.

RE,CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2002:582203 CAPLUS <<LOGINID::20090113>>

Correction of: 2002:10728

DN 137:104768

Correction of: 136:65179

TI Diagnosis and therapy of diseases associated with signal transduction by detection of single nucleotide polymorphism and cytosine methylation in chemically modified genomic DNA

IN Olek, Alexander; Piepenbrock, Christian; Berlin, Kurt

PA Epigenomics Ag, Germany

SO PCT Int. Appl., 24 pp.

CODEN: PIIXD2

DT Patent

LA English

FAN.CNT 69

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000926	A2	20020103	WO 2001-EP7472	20010629
WO 2002000926	A3	20021121		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CL, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10032529	A1	20020207	DE 2000-10032529	20000630
AU 2001077487	A	20011023	AU 2001-77487	20010406
EP 1360319	A2	20031112	EP 2001-955278	20010406
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 2000544	A1	20081210	EP 2008-12765	20010406
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
AU 2001089617	A	20020108	AU 2001-89617	20010629
EP 1297185	A2	20030402	EP 2001-969326	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
DE 20121961	U1	20040129	DE 2001-20121961	20010629
DE 20121971	U1	20040205	DE 2001-20121971	20010629
DE 20121979	U1	20040205	DE 2001-20121979	20010629
DE 20121966	U1	20031224	DE 2001-20121966	20010702
DE 20121963	U1	20040129	DE 2001-20121963	20010702
DE 20121967	U1	20040129	DE 2001-20121967	20010702
DE 20121975	U1	20040219	DE 2001-20121975	20010702
DE 20121978	U1	20040219	DE 2001-20121978	20010702
EP 1676927	A2	20060705	EP 2006-2091	20010702
EP 1676927	A3	20061206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1942197	A1	20080709	EP 2007-119103	20010901
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
AT 339520	T	20061015	AT 2002-90203	20020605
ES 2272636	T3	20070501	ES 2002-90203	20020605
US 20040067491	A1	20040408	US 2003-240454	20030311

AU 2003204553	A1	20040108	AU 2003-204553	20030605
AU 2003204553	B2	20071129		
JP 2004008217	A	20040115	JP 2003-160375	20030605
US 20040023279	A1	20040205	US 2003-455212	20030605
NZ 541308	A	20061222	NZ 2005-541308	20050715
AU 2006213968	A1	20061019	AU 2006-213968	20060915
PRAI DE 2000-10032529	A	20000630		
DE 2000-10043826	A	20000901		
DE 2000-10019058	A	20000406		
DE 2000-10019173	A	20000407		
DE 2000-10044543	A	20000905		
AU 2001-275663	A	20010406		
AU 2001-75663	A	20010406		
EP 2001-969303	A3	20010406		
WO 2001-EP4016	W	20010406		
WO 2001-EP7472	W	20010629		
EP 2001-962813	A3	20010702		
EP 2001-967115	A	20010702		
EP 2001-980315	A3	20010901		
NZ 2001-524229	A1	20010901		
EP 2002-90203	A	20020605		

AB The invention relates to chem. modified genomic sequences of genes assocd. with signal transduction, an oligonucleotide directed against said sequence and/or PNA oligomers for the detection of the methylation state of cytosine of genes assocd. with signal transduction. The present invention is based on the discovery that cytosine methylations patterns in genomic DNA are particularly suitable for diagnosis and/or therapy of diseases assocd. with signal transduction. Thus, the chem. Modified genomic sequences of genes assocd. with signal transduction, and oligonucleotides and/or peptide nucleic acid oligomers for detecting the cytosine methylation state of signal transduction genes are provided. Specific reaction of bisulfite and subsequent alk. hydrolysis converts cytosine to uracil, which corresponds to thymidine in its base pairing behavior. However, 5-methylcytosine remains unmodified under these conditions. Consequently, the original DNA is converted in such a manner that methylcytosine, which originally could not be distinguished from cytosine by its hybridization behavior, can now be detected as the only remaining cytosine using "normal" mol. biol. techniques. The oligomer probes according to the present invention, contg. at least one CpG dinucleotide, constitute important and effective tools which make it possible to ascertain the genetic and epigenetic parameters of genes assocd. with signal transduction. The invention is exemplified by gene AR in which a specific CG-position is analyzed for methylation. The Sequence Listing was provided as an electronic file, but was not made available in the release of this patent.

=> D L9 BIB AB 22-24

'BIB' IS NOT A VALID FORMAT

'AB' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ALL

L9 ANSWER 22 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

LOCUS (LOC): CQ903957 GenBank (R)
 GenBank ACC. NO. (GBN): CQ903957
 GenBank VERSION (VER): CQ903957.1 GI:55785349
 CAS REGISTRY NO. (RN): ***784072-70-4***
 SEQUENCE LENGTH (SQL): 21
 MOLECULE TYPE (CT): DNA; linear
 DIVISION CODE (CI): Patent
 DATE (DATE): 16 Nov 2004
 DEFINITION (DEF): Sequence 143 from Patent WO2004094671.
 SOURCE: synthetic construct
 ORGANISM (ORGN): synthetic construct
 other sequences; artificial sequences
 REFERENCE: 1
 AUTHOR (AU): Vollmer,J.; Jurk,M.; Lipford,G.B.; Schetter,C.;
 Forsbach,A.; Krieg,A.M.
 TITLE (TI): Methods and products for identification and assessment
 of tlr ligands
 JOURNAL (SO): Patent: WO 2004094671-A 143 04-NOV-2004; Coley
 Pharmaceutical GmbH (DE); Coley Pharmaceutical Group,
 Inc. (US)

FEATURES (FEAT):

Feature Key	Location	Qualifier
-------------	----------	-----------

source	1..21	/organism="synthetic construct" /mol-type="unassigned DNA" /db-xref="taxon:32630" /note="Immunostimulatory nucleic acid"
--------	-------	--

SEQUENCE (SEQ):

I tcgtcggtt tcggtcgttt

L9 ANSWER 23 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

LOCUS (LOC): CQ892106 GenBank (R)
 GenBank ACC. NO. (GBN): CQ892106
 GenBank VERSION (VER): CQ892106.1 GI:55164664
 CAS REGISTRY NO. (RN): ***774441-79-1***
 SEQUENCE LENGTH (SQL): 21
 MOLECULE TYPE (CT): DNA; linear
 DIVISION CODE (CI): Patent
 DATE (DATE): 1 Nov 2004
 DEFINITION (DEF): Sequence 149 from Patent WO2004087203.
 SOURCE: synthetic construct
 ORGANISM (ORGN): synthetic construct
 other sequences; artificial sequences
 REFERENCE: 1
 AUTHOR (AU): Davis,H.I.; Mccluskie,M.J.
 TITLE (TI): Immunostimulatory nucleic acid oil-in-water
 formulations and related methods of use
 JOURNAL (SO): Patent: WO 2004087203-A 149 14-OCT-2004; Coley

661 titataattt gtaaattaa ittaaggat ttagttaa aaattaaga accgttat
 721 ttgtgggtt ttttcggag gggtaggg ttagtttt tgaaggtt tattttata
 781 atgttgtgg atattagat tttaaatag gaatttaaq aangtaattt tgitttagt
 841 atgtgtgt ttttgaaat ttttgtaa aattttata atgggtgtgaa tttaaggatt
 901 tagttttt attgeaat ttttgggat tttaaataq tattatggt gttagaggt
 961 aagggttagg agaggatfgg tagttaggg tttttttt tagggattt tgltttgg
 1021 taatttttg tttaaanga gtttggtagg tgattttgtt agaaatit atatattt
 1081 gtattataa ttattttt tagtttaat ttgtttaaa gaagggtgg tggtaaagt
 1141 atagatgtt tgtttttg gaattttat aaattttat gaangttttt ttattttat
 1201 ttttttat tttttttt taattttt ttttggggat ttatattata ttgaaagat
 1261 agaagggtt tgatgtgt atatgtat aaataatag atttggggat atttggatt
 1321 taaaatgaaa tttaattttt tttaatttt tagatttaaa cgtttttat tttttatg
 1381 gatattataa atgtatgtt atttatgtgg tggtgggtt tttttttgt tttttttat
 1441 taaaataaaaa taaaagaaat ttttgggg tttgtgtttt gtattttt atgtttaggg
 1501 atatattttt tagttat atgtgggtt ttttttata ttatgtatg atatttatg
 1561 ttgggtgtt ttatattttt taatgtatg tagaaaggat atttttttt tgittttatg
 1621 taaaatggg tgatgtttaa aaaaatgtt aggttaatg tgggttataa taaaagagg
 1681 atagggtgtt ttatgtttt tttttttt tttttttt tgatattt tttttttt
 1741 gggtttttt aaattttatg taaaatggg gtttgaattt aaattttat tttttatg
 1801 attttttt ttagttttttt tttttttt gttttttt tagttttttt tttttttt
 1861 tagttttaa aaatgtatataa gttttttt aggddaaaaaa taattttggg tttttttt
 1921 ttttttttttttttaatg taaaatggg tttttttt tttttttt tttttttt
 1981 gtttttttta attttttatg taaaatggg tttttttt tttttttt tttttttt
 2041 taagaaacca ttttttttt tttttttt tttttttt tttttttt tgatgttta
 2101 attttttt attttttttagt gttttttt tttttttt tttttttt tttttttt
 2161 gttttttttt tttttttt tttttttt gttttttt atgtttaggg tgtttttt
 2221 ttttttttgg ttttttttgg tgatgttgg cttttttt tttttttt gttttttt
 2281 ttttttttgg ttttttttgg atatgtat tttttttt tttttttt tttttttt
 2341 aaattttat tttttttt tttttttt tttttttt tttttttt tttttttt
 2401 gataaaaaaa aggtttttttt tttttttt tttttttt tttttttt
 2461 tagtattttt ttttttttgg tttttttt tttttttt tttttttt
 2521 tgatgttta tttttttt tttttttt tttttttt tttttttt
 2581 ttttttttgg gataatgg gtagtgcgtt aatgtttt tttttttt
 2641 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 2701 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 2761 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 2821 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 2881 aaaaatattt atatttttt tttttttt tttttttt tttttttt
 2941 ttttttttgg agatattat taaaatgtt tttttttt tttttttt
 3001 gggtttttt tttttttt tttttttt tttttttt tttttttt
 3061 agttttttt tttttttt tttttttt tttttttt tttttttt
 3121 agttttttt tttttttt tttttttt tttttttt tttttttt
 3181 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3241 agttttttt tttttttt tttttttt tttttttt tttttttt
 3301 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3361 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3421 atatgtgtt tttttttt tttttttt tttttttt tttttttt
 3481 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3541 gttttttttt tttttttt tttttttt tttttttt tttttttt
 3601 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3661 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3721 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3781 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3841 ttttttttgg tttttttt tttttttt tttttttt tttttttt
 3901 ttttttttgg tttttttt tttttttt tttttttt tttttttt

10561 gtttattat atgataaata taatttaat tttgtattat tttggggta taataaagg
 10621 aaatatttgta gtgttattt ttatgtta ttgttattt aaatggata ttttgaaaa
 10681 ttataataa tttttgtat tttaaatgtta ttataatta ttgttagat ttttttat
 10741 ttataaataa ttttttaaaat ttgttattt ttttgatgt aatgttaaat agaaaatgt
 10801 gtaaaatata ttttgggggt tttggggaga gtgaatggg taattttgg gggttattt
 10861 tttaaaattt tattttata algttattt atttaattt ttataaattt atataattt
 10921 tgattttttt ataaatattt ttataaata ttatgttt ttattttat attttata
 10981 gagtagattt tattttaaaat aggaaattttt tttaaagttt ttatgttaa gttagagatt
 11041 gtttttgtt ttttttat tttttttttt tgtaaaat tttttttttt ttatgtttttaa atttttagt
 11101 ttatgtata agggaggtaa taggtttagt taggtttaga gaganatgg agaatttag
 11161 altaggtt tttttttttt ttgttattt ttatgggtaa agttttttttaa ahggaaaa
 11221 ttggaaatgtt acgtttaaaaaa tttttttttt tttttttttt tttttttttt
 11281 tttagaaata tttaaaaga aattttatgt tttttttttt ttgttattt agggatattt
 11341 aaatgtgtta gtttattt tagttttgtta attttttttt aattttttt tttttttt
 11401 tttttttttt tttaggtt agaaattttt ttgttattt tttttttttt tttttttt
 11461 aattttatgt tttttttttt ttgttattt ttgtttaatg tttttttttt tttttttt
 11521 cgggtttttt ggtttttttt tttttttttt ttgttattttaa taatgtttt aatttttt
 11581 gagacgggg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 11641 ttgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 11701 aattttttttt tttttttttt aatgttaatg tttaaaatgttta ttatataattt ttggatcgt
 11761 ttgttggaaat ttgttgggtt gaaatgtttt tttttttttt tttttttttt
 11821 aattttataa ttgttgggtt tagggatgg taggtttagg ttatgttaa gtgttag
 11881 tttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 11941 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12001 gagaatataa ttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12061 taatataatata aatgtatgggg tttttttttt tttttttttt tttttttttt tttttttttt
 12121 aggaatgttta tagttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12181 gaagtttat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12241 gtgtttttgtt aggggtttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12301 tagggcgat aggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12361 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12421 ggggtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12481 agttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12541 gtgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12601 aatgtttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12661 ggtatgttta aataatgggg tttttttttt tttttttttt tttttttttt tttttttttt
 12721 gattttttttt ggttgggg tttttttttt tttttttttt tttttttttt tttttttttt
 12781 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12841 gggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12901 aattttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 12961 gtatgtttt aattttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 13021 agttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 13081 atattttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt

>>